Migayron et al. Front Immunol➜ DOI: 10.3389/fimmu.2024.1405215Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?This is an interesting review which approaches indirectly some of the paradoxical findings observed using targeted therapies in AD. Silverberg et al JAAD➜ DOI: 10.1016/j.jaad.2024.05.023Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis [...] Read More
What PubMed tell us about current trends in AD research? Dear Colleagues, Dear Friends, Since the approval of dupilumab for severe adult AD by the FDA in 2017, published AD research has been tremendously driven by RCTs and associated research concerning dupilumab and other new systemic/ topical therapies designed to control TH2 inflammation. The influence […]
Read More
We are proud to be a participating institution with World Health Organization on Global Initiative on AI for Skin Conditions! This WHO Neglected Tropical Diseases (NTD)-led Global Initiative discusses progress, challenges, gaps and solutions in developing and implementing artificial augmented intelligence-based apps as a capacity building and monitoring tool for skin NTDs and selected common skin conditions […]
Read More
The 2024 Rajka Medal and Prize will be attributed, please have a look at the criteria to apply, this year will be very competitive! From 2024, an accompanying prize of 15.000 EUR will be given to the awardee to contribute to further research at his/her institution. In memory of Professor Georg RAJKA and his pioneering […]
Read More
Dear Colleagues, Dear Friends, Our May 2024 newsletter features ISAD collaboration with ILDS on the World Skin Health Day (WSHD) in Guinea and Madagascar, a national program to promote skin health including AD in Mauritania, the opening of the RAJKA2024 Call for Abstracts (ISAD Doha) and a focus on its pre-meeting: Patient-Centered Care in Atopic […]
Read More
Carmanius et al, JEADV 2024➜ DOI: 10.1111/jdv.20076A cross-sectional study based on the 24-year follow-up from the population-based birth cohort linked with dispensing data from the National Swedish Drug Register confirms that a large proportion of young adults with AD is undertreated or untreated. Kook et al, JEADV 2024➜ DOI: 10.1111/jdv.20053Misdiagnosis of AD or confounding skin diseases in [...] Read More
Organized by SOMADER May 22, 2024, Madagascar The ISAD is happy to participate to the next World Skin Health Day organized by the Malagasy Society of Dermatology (SOMADER) with a regional and global focus on AD challenges. This programme highlights also the new WHO policy around skin NTDs in low resource countries combined with the […]
Read More
May 11, 2024, Nouakchott, Mauritania ISAD Society President Alain TAÏEB visited Mauritania and met the members of the National Dermatology Society (SMD, President Prof BALL second rank right) on the occasion of very interesting meeting organized on May 11th jointly by the SMD and the Ministry of Health. Mariem KEBE (yellow, middle of second rank), […]
Read More
Dear Colleagues, Dear Friends, Our April 2024 newsletter features report on our One Health event, our Research Fellowships and the RAJKA 2024 Symposium in Doha, along with a curated selection of the latest publications on PubMed that are worth reading. Alain TAÏEBPresident ISAD Examining Atopic Dermatitis through the One Health concept REPORT ON OUR SPRING […]
Read More
Federica Casetti, Cristina Has➜ First published: 03 March 2024 - DOI: 10.1111/ddg.15358Dupilumab improves congenital ichthyosis in the context of a filaggrin pathogenic variant. This report from Germany confirms other reports of a response of rare ichthyotic conditions such as Netherton’s syndrome and trichothiodystrophy to targeting IL-4Rα, and that the common FLG mutations may accentuate the inflammatory phenotype [...] Read More